Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCEMC6)

Drug Name

GS-1811 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-C chemokine receptor type 8 (CCR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CCX-832	DMD8QHV	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[3]
viral macrophage inflammatory protein-II	DMAXOPS	Discovery agent	N.A.	Investigative	[4]
ZK 756326	DMP089G	Discovery agent	N.A.	Investigative	[5]
I-309	DM7QE51	Discovery agent	N.A.	Investigative	[6]
N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide	DMQS9OH	Discovery agent	N.A.	Investigative	[7]
N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide	DM74KHG	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 8 (CCR8)	TTE836A	CCR8_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05007782) A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
2	Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology. 2022 Nov 4;11(1):2141007.
3	Increased Expression of Chemerin in Squamous Esophageal Cancer Myofibroblasts and Role in Recruitment of Mesenchymal Stromal Cells. PLoS One. 2014; 9(8): e104877.
4	HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem. 1999 Jul 30;274(31):21569-74.
5	Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol. 2006 Jan;69(1):309-16.
6	The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol. 1998 Jul 15;161(2):547-51.
7	Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem. 2007 Feb 8;50(3):566-84.